Fulgent Genetics (NASDAQ:FLGT) Issues FY 2025 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of -0.650–0.650 for the period, compared to the consensus EPS estimate of -0.460. The company issued revenue guidance of $310.0 million-$310.0 million, compared to the consensus revenue estimate of $324.2 million. Fulgent Genetics also updated its FY25 guidance to $(0.65) EPS.

Fulgent Genetics Stock Performance

Shares of FLGT opened at $15.45 on Friday. The company’s 50 day moving average price is $17.32 and its 200 day moving average price is $19.46. Fulgent Genetics has a 52 week low of $15.21 and a 52 week high of $25.11. The company has a market capitalization of $472.57 million, a PE ratio of -2.80 and a beta of 1.39.

Analyst Upgrades and Downgrades

FLGT has been the topic of a number of research analyst reports. Piper Sandler lowered their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Monday, November 11th. StockNews.com cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.